Skip to main content

Market Overview

DA Davidson Out Bullish On Landec: 'We Can Justify A Constructive Stance'

DA Davidson Out Bullish On Landec: 'We Can Justify A Constructive Stance'

While margin initiatives are underway in Landec Corporation (NASDAQ: LNDC)'s Curation Foods segment, the Lifecore Biomedical segment is poised to form secular tailwinds in the pharmaceutical industry, according to D.A. Davidson.

The Analyst

Brian Holland initiated coverage of Landec with a Buy rating and $14 price target.

The Thesis

The initiatives undertaken by Landec’s recently appointed CEO Dr. Albert Bolles to improve profitability in the Curation Foods segment appear achievable, Holland said in a Friday initiation note. 

The initiatives are aimed at simplifying Curation Foods’ business, within which the company enacted an enterprise-wide operation management system to improve efficiencies, as well as a cost-out program to mitigate labor, freight and raw material cost pressures, the analyst said. 

Regardless of the actual margin expansion, “we can justify a constructive stance on relatively conservative assumptions,” he said. 

The pharmaceutical industry has been increasingly outsourcing new product development and manufacturing to capable contract development and manufacturing organizations, and the Lifecore Biomedical segment is poised to benefit from this trend, Holland said. 

While this segment’s hyaluron and private label products were already performing well among ophthalmic surgical companies, they could also be employed by oncology, ENT, pulmonary, neurology and general surgery clients, according to D.A. Davidson. 

Price Action

Landec shares were down 0.55% at $10.91 at the time of publication Friday. 

Related Links:

Benzinga's Top Upgrades, Downgrades For August 23, 2019

Insider Buys Of The Week: Abeona Therapeutics, Kinder Morgan, Landec

Latest Ratings for LNDC

Jan 2020Barrington ResearchDowngradesOutperformMarket Perform
Sep 2019Barrington ResearchInitiates Coverage OnOutperform
Aug 2019DA DavidsonInitiates Coverage OnBuy

View More Analyst Ratings for LNDC
View the Latest Analyst Ratings


Related Articles (LNDC)

View Comments and Join the Discussion!

Posted-In: Brian Holland D.A. DavidsonAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga

Latest Ratings

NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at